Perspectives for Clinical Translation of Adipose Stromal/Stem Cells

Abstract

Adipose stromal/stem cells (ASCs) are an ideal cell type for regenerative medicine applications, as they can easily be harvested from adipose tissue in large quantities. ASCs have excellent proliferation, differentiation, and immunoregulatory capacities that have been demonstrated in numerous studies. Great interest and investment have been placed in efforts to exploit the allogeneic use and immunomodulatory and anti-inflammatory effects of ASCs. However, bridging the gap betweenin vitroandin vivostudies and moving into clinical practice remain a challenge. For the clinical translation of ASCs, several issues must be considered, including how to characterise such a heterogenic cell population and how to ensure their safety and efficacy. This review explores the different phases ofin vitroand preclinical ASC characterisation and describes the development of appropriate potency assays. In addition, good manufacturing practice requirements are discussed, and cell-based medicinal products holding marketing authorisation in the European Union are reviewed. Moreover, the current status of clinical trials applying ASCs and the patent landscape in the field of ASC research are presented. Overall, this review highlights the applicability of ASCs for clinical cell therapies and discusses their potential.

Mechanochemical Patternable ECM‐Mimetic Hydrogels for Programmed Cell Orientation

“…[ 49,76 ] Herein, hASCs were selected due to their multilineage differentiation potential and applicability in regenerative medicine strategies. [ 77 ] These cells were encapsulated within oxLAM‐Gelatin hydrogels in order to validate the cytocompatible nature of the crosslinking chemistry, as well as the suitability of the biomaterial platform itself for prolonged culturing periods.…”

Adipose‐derived stem cells: An appropriate selection for osteogenic differentiation

“…In presenting clinical cases and trials, more autologous cells have been used. The use of allogeneic and autologous MSC-based therapies have some challenges (Patrikoski, Mannerstrom, & Miettinen, 2019) (Patrikoski et al, 2019). Harvesting allogeneic MSCs from healthy young people can be a promising alternative to overcome these restrictions (J.…”

Polyploid Adipose Stem Cells Shift the Balance of IGF1/IGFBP2 to Promote the Growth of Breast Cancer

“…Adipose-tissue derived stem cells (ASCs) are especially popular, as these cells can be easily harvested in large quantities. ASCs have a great potential to proliferate, to differentiate into various cell lineages and to modulate immune responses, therefore they seem to be ideal for the treatment of orthopedic or inflammatory diseases (1). ASCs have multiple roles in regeneration: they provide source for cell-renewal, and secrete paracrine factors for cell growth, revascularization, immunosuppression, and wound-healing.…”

“…ASCs have multiple roles in regeneration: they provide source for cell-renewal, and secrete paracrine factors for cell growth, revascularization, immunosuppression, and wound-healing. In vivo studies suggest that ASCs may be used for the treatment or adjunctive therapy for multiple sclerosis, ischemic stroke, glioblastoma, spinal fusion, chronic liver failure, acute kidney injuries, myocardial ischemia, chronic obstructive pulmonary disease, osteoarthritis, and inflammatory bowel disease (1,2). However, fewer studies reach clinical phase II or beyond, and the first marketing authorization of an allogeneic stem cell therapy was approved in 2018 for the treatment of complex perianal fistulas in Crohn's disease (3).…”